Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations

Int J Mol Sci. 2023 Feb 13;24(4):3739. doi: 10.3390/ijms24043739.

Abstract

Neurodegenerative diseases comprise a wide spectrum of pathologies characterized by progressive loss of neuronal functions and structures. Despite having different genetic backgrounds and etiology, in recent years, many studies have highlighted a point of convergence in the mechanisms leading to neurodegeneration: mitochondrial dysfunction and oxidative stress have been observed in different pathologies, and their detrimental effects on neurons contribute to the exacerbation of the pathological phenotype at various degrees. In this context, increasing relevance has been acquired by antioxidant therapies, with the purpose of restoring mitochondrial functions in order to revert the neuronal damage. However, conventional antioxidants were not able to specifically accumulate in diseased mitochondria, often eliciting harmful effects on the whole body. In the last decades, novel, precise, mitochondria-targeted antioxidant (MTA) compounds have been developed and studied, both in vitro and in vivo, to address the need to counter the oxidative stress in mitochondria and restore the energy supply and membrane potentials in neurons. In this review, we focus on the activity and therapeutic perspectives of MitoQ, SkQ1, MitoVitE and MitoTEMPO, the most studied compounds belonging to the class of MTA conjugated to lipophilic cations, in order to reach the mitochondrial compartment.

Keywords: mitochondria; mitochondrial medicine; mitophagy; neurodegenerative disorders; neuroinflammation.

Publication types

  • Review

MeSH terms

  • Antioxidants* / metabolism
  • Cations / metabolism
  • Humans
  • Mitochondria / metabolism
  • Neurodegenerative Diseases* / metabolism
  • Organophosphorus Compounds / metabolism
  • Oxidative Stress
  • Ubiquinone / metabolism

Substances

  • Antioxidants
  • Organophosphorus Compounds
  • Cations
  • Ubiquinone

Grants and funding

This research received no external funding.